Literature DB >> 29077579

Acquisition of Somatic NRAS Mutations in Central Nervous System Melanocytes: A Predisposing Risk Factor to Primary Melanoma of the Central Nervous System, a Frequently Forgotten Pitfall in Congenital Nevi.

Maria C Garrido1, Lidia Maroñas-Jiménez2, Carlos Morales-Raya2, Yolanda Ruano1, Jose L Rodriguez-Peralto1.   

Abstract

Congenital melanocytic nevi (CMN) are benign melanocytic proliferations that are usually present at birth. A somatic mosaicism for an NRAS point mutation is responsible for the several phenotypic abnormalities that may be associated with congenital nevi. We report the case of a 7-year-old boy with a proliferative nodule (PN) arising in a Giant CMN completely excised and with several visceral and intraspinal melanoma metastases with no evidence of primary cutaneous melanoma. The careful analysis of the clinical, morphologic, and molecular features allowed the distinction of between the benign PN (BPN) and the melanoma. The BPN showed a characteristic comparative genomic hybridization pattern with gains or losses of whole chromosomes, whereas the melanoma displayed gains or losses involving complex partial chromosomal copy number gains or losses. Leptomeningeal melanocytes are more susceptible to transformation by oncogenic NRAS than cutaneous melanocytes, and central nervous system melanomas are more common than cutaneous melanomas in the setting of CMN. Thus, it has been recommended to characterize the congenital disease in patients with 2 CMN at birth, independently of size and site, with a single magnetic resonance imaging screening younger than the age of 1 year.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29077579     DOI: 10.1097/DAD.0000000000001039

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  1 in total

1.  Primary melanoma of leptomeninge in a patient with giant congenital melanocytic nevus.

Authors:  Adriana Kamilly Leitão Pitman Machado; Débora Bacellar Cruz Nunes; Francisca Regina Oliveira Carneiro; Alena Margareth Darwich Mendes
Journal:  An Bras Dermatol       Date:  2020-03-18       Impact factor: 1.896

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.